Articles tagged with Hiv Research
A randomized trial found that daily doses of cheap antibiotic co-trimoxazole nearly halved the mortality rate compared to placebo among HIV-infected children in Zambia. The study suggests that all children with clinical features of HIV infection in Africa should receive co-trimoxazole prophylaxis, regardless of age or CD4 count.
Researchers at GlaxoSmithKline have been awarded grants to develop new treatments for HIV/AIDS. Dr. Yaoxing Huang's work focuses on designing a protein that can block all three steps of the viral entry process, while Olaf Kutsch aims to identify potential inhibitors of HIV transcription using a novel screening system.
The Gerontological Society of America has conferred the 2004 Nathan Shock New Investigator Award to Dr. Marciniak for his pioneering work in gene regulation by the AIDS virus HIV. His research expertise bridges two critical areas, aging and cancer, making him a prime example of a geriatric oncologist.
The seven-year contract will target non-HIV STIs and include microbicides, vaccines, STI treatments and diagnostic products. Students from international partners can participate in a yearlong program at UCSF for certification and mentoring.
A study found that African-American patients treated by white doctors receive HIV medications nearly four months later than those treated by African-American doctors. Better communication and trust between patient and doctor of the same race may explain these differences.
Researchers successfully targeted the key HIV protein Nef using small molecules, disrupting its interaction with other proteins. This breakthrough may lead to new drug therapies with improved treatment options.
A study published in BMC Medicine found that using visual aids significantly improved pregnant women's understanding of HIV study information. The researchers suggest that the current informed consent process is inadequate and should be revised to effectively communicate information.
A study suggests that aging HIV patients are at risk of developing dementia due to the accumulation of amyloid beta in their brains. Researchers found a correlation between years of infection and increased amyloid beta levels, suggesting that good clinical control of plasma HIV may not be enough to prevent related pathologies.
The Yale team will conduct research on implementing structural interventions among high-risk groups in southern India, aiming to reduce HIV transmission and promote healthier behavior. The project, funded by the Bill & Melinda Gates Foundation, aims to address social, economic, and normative factors that contribute to HIV risk.
A recent study found that HIV clinicians with fatalistic attitudes are less likely to provide prevention counseling to HIV-positive patients. The study surveyed 618 patients and found a correlation between provider fatalism and reduced reporting of prevention services.
A mobile testing van was introduced in Zimbabwe's Epworth and Seke areas, offering free rapid HIV tests with same-day results. The initiative reduced structural barriers by providing convenient access to testing and increased acceptance of rapid tests due to same-day results.
A recent study by researchers at the Gladstone Institute of Virology and Immunology investigated potential superinfection involving variations within HIV-1B. The findings, presented at the XV International AIDS Conference, suggest that superinfection may be restricted to a short window period after seroconversion.
In a study published in the Journal of Acquired Immune Deficiency Syndromes, researchers found that African participants took on average 91-94% of prescribed HIV medications. The study, which followed 34 participants over 12 weeks, used multiple adherence measures and observed high rates of viral suppression.
Researchers found six HIV patients who started treatment early became test-negative for the virus. The study suggests that reducing HIV to low levels can help boost the immune system's response to the virus.
A six-month study found that providing primary care to nearly 2,000 HIV-infected patients costs an average of $30 USD per visit. The breakdown includes staff salaries, laboratory tests, and medications.
A randomized trial found that two short drug regimens for infants at birth reduced mother-to-child transmission of HIV compared to a single regimen. The study suggests several options for prevention, including voluntary counseling and testing, standard NVP prophylaxis, and postexposure prophylaxis.
Researchers at Michigan State University have devised new ways to understand the impact of AIDS on families in rural Africa. The study shows that the disease is not always devastating, but rather cripples some families while leaving others with a better chance of enduring.
A study by Brown University researchers found high prevalence of life-threatening and contagious infections among incoming inmates. Nearly 20% tested positive for hepatitis B, highlighting the need for vaccination to prevent transmission upon release into the community.
The Lancet discusses new design changes to the journal, including open-access policies and electronic document posting. The article also explores various HIV/AIDS strategies for developing countries, including expanded access to treatment and prevention efforts. Researchers emphasize the importance of local solutions and community-led ...
A study found that 71% of Ugandans were aware of vaccines' preventive function, and 77% were willing to participate in HIV-preventive vaccine trials. However, education on the severity of HIV/AIDS and the importance of vaccines for men is still needed.
A study found that HIV's gp120 protein can repel immune cells, dubbed fugetaxis, which could lead to a new therapeutic approach to block this activity. This mechanism may also apply to other viruses, such as pox and papilloma viruses.
The Case CFAR, located in the Midwest, has been renewed with an $8 million NIH award for a five-year period. This renewal recognizes the center's strong AIDS research program and its collaboration with local and international institutions.
The GlaxoSmithKline Drug Discovery and Development Research Grant Program provides funding for HIV/AIDS research, focusing on novel therapies, vaccines, and microbicides. Researchers can apply for grants ranging from $25,000 to $150,000 to develop innovative treatments and submit proposals for publication.
King Chung's research shows that combining hearing aid technologies with cochlear implants reduces background noise, enhances speech understanding, and improves sound quality. Cochlear implant users prefer conditions with advanced hearing aid preprocessing.
A recent study found that HIV infection progresses to AIDS at a rate of 7.4 years in developing countries, compared to 11 years in Western developed nations. The study also revealed a higher mortality rate among men living in developing countries.
Researchers sequenced genetic material from a new strain of SIV in chimpanzees near Kisangani, Democratic Republic of Congo. The new strain is not related to HIV-1 and confirms that HIV-AIDS did not originate from oral polio vaccines.
A new study suggests that male circumcision may protect against HIV-1 infection by removing the foreskin's high density of specific cellular targets. The study found a highly significant and specific protective effect of male circumcision on HIV-1 acquisition rates, but no protective effect against other STIs.
Researchers found simian foamy virus (SFV) in 1% of Cameroonian villagers, linked to hunting and butchering primates. The study suggests retroviral zoonosis is widespread, highlighting the need for economic alternatives to reduce human-primate contact.
Research finds HIV-positive men who have persistent GBV-C infection survive longer, but the exact reason is unknown. The study of 271 participants found that those with long-term GBV-C infection lived up to 11 years after contracting HIV.
Researchers have identified TRIM5-alpha as a natural blocker of the HIV-1 virus, which could lead to new strategies for preventing infection that causes AIDS. The protein is found in human cells but is less effective than the monkey version, and its potency may vary among individuals.
Researchers at UW-Madison find that mutations allowing AIDS viruses to escape immune detection also hinder their ability to grow after transmission. The discovery may help design vaccines targeting the virus's most vulnerable spots.
The Netherlands has established two new research centers, NIVAREC and PRIOR, to develop and produce flu vaccines and tackle poverty-related infectious diseases. The centers aim to strengthen cooperation between researchers from different institutes and foster knowledge infrastructure in developing countries.
A new software application called IRIDESCENT allows researchers to easily identify commonalities in research data and relate them to their studies, saving time and speeding discovery. The system emulates the scientific thought process and can compile diverse facts to present a list of 'hypotheses' for finding hidden knowledge.
Researchers found that HIV uses Nef to activate Rac activity in DOCK2ELMO1 complex, disrupting T cell migration and interaction with other lymphocytes. This study provides biochemical evidence for Nef's role in subverting immune response pathways controlled by receptors on T cells.
Leading medical schools and research institutions criticize a US-sponsored HIV vaccine trial in Thailand due to the absence of independent expert input. The trial's high cost of $119 million has also raised concerns about its scientific merit.
Researchers at Mayo Clinic implant human blood stem cells into fetal pigs, revealing the presence of hybrid cells with both human and pig DNA. These findings may help explain how viruses jump from animals to humans, paving the way for discovery about disease origins like AIDS.
The ICBG program supports 12 groups in identifying new drugs through screening of flora and fauna while protecting biodiversity. Projects include evaluation of traditional medicine practices, discovery of safe new agents and training for host-country scientific institutions.
A study by UCLA researchers found that individuals with shy personalities tend to have higher viral loads and faster disease progression, even on antiretroviral therapy. This suggests that high-stress individuals may be more susceptible to HIV replication due to their heightened nervous system response.
A study found that antiretroviral treatment significantly reduced the risk of HIV transmission from HIV-infected individuals to their partners. However, an increase in unprotected anal intercourse offset this benefit, highlighting the need for prevention interventions alongside treatment.
The GSK Drug Discovery and Development Research Grant Program awarded $125,000 grants to Paul Bieniasz for genetic screening of cyclic peptides and Michael Farzan for tyrosine-sulfated peptides. Additionally, Michael H. Malim received a grant for his research on the Vif gene, which plays a critical role in HIV infection.
A UCSD study of 1,049 HIV-infected children found that specific genetic mutations can affect disease progression and immune system response to the virus. Children with certain polymorphisms, such as CCR5-delta32, showed slower disease progression, while others were more susceptible to worsening symptoms.
Researchers found that green tea catechin EGCG effectively prevents HIV from binding to human T cells, a breakthrough in the fight against HIV. Further research is needed to explore the potential clinical application of EGCG as an anti-HIV drug.
Patients who view their HIV as an opportunity for personal growth tend to cope better with their disease. Researchers found that more than 73 percent of low-income HIV patients were clinically depressed, highlighting the need for supportive therapy.
A study by Case Western Reserve University researchers found that human beta defensins 2 and 3 in the mouth's lining can inhibit HIV-1 replication and regulate viral receptors. This discovery has potential for developing new medical interventions using natural products to prevent HIV infection, particularly in high-risk areas.
Researchers found that Peptide T significantly reduced HIV levels in cellular reservoirs, with some participants experiencing undetectable virus and increased CD4 counts. The therapy showed promise as a complement or alternative to existing treatments for HIV/AIDS.
A randomized clinical trial will test whether daily tenofovir prevents HIV infection in 800 high-risk, uninfected Cambodian women. The study aims to evaluate the effectiveness of the antiviral drug for preventing HIV-1 transmission in people.
Research at UCSF found that patients taking 80% or more of their antiretroviral medications developed twice as many resistance mutations as those taking less than 40%. Despite this, excellent adherence remains the best way to prevent HIV/AIDS and prolong life with resistant virus.
The UNC-led trial is the first human test of an HIV vaccine pioneered at UNC. The vaccine targets cells in lymph nodes and induces an immune response by expressing a small section of genetic material from HIV, aiming to protect against disease if exposed. Researchers hope to refine the vaccine for subsequent generations.
A new computer-based system, ACASI, was tested with Zimbabwean women, yielding more accurate data on key HIV risks. The tool helped overcome cultural issues and social desirability bias in face-to-face interviews.
A study of 181 sexually active Zimbabwean women found that diaphragms can be used without a partner's knowledge to prevent HIV transmission. The researchers suggest that this method could provide an additional tool for HIV prevention, particularly for women who do not have access to condoms or other forms of protection.
The trial, led by Saint Louis University, is a phase I trial investigating the safety and immune response of EP HIV-1090 vaccine candidate. Participants will receive the vaccine or placebo over 18 months, with observations to assess its potential effectiveness against HIV.
A new study published in Nature Medicine has found that certain human genes can predict the progression rate of AIDS in infected individuals. The researchers analyzed data from a large group of homosexual men with HIV and found that those with specific HLA protein types were more likely to succumb to the disease quickly.
Scientists have determined the structure of the 2G12 antibody, which neutralizes HIV by binding to sugars on its surface. The antibody's unique structure could provide a template for designing an antigen that triggers the body to produce it, potentially leading to an HIV vaccine.
Researchers have identified a molecular fingerprint unique to individuals with HIV-associated dementia (HAD), suggesting the potential development of a simple blood test for its diagnosis. The study used proteomics to analyze protein patterns in patients and found correlations between certain proteins and HAD.
India's HIV prevalence rate is less than 1 percent, but a looming pandemic on the horizon due to shifting demographics and changing cultural values. The researchers recommend targeted prevention programs for high-risk groups, such as prostitutes and men who have sex with men, and offer circumcision as an additional avenue of prevention.
A study found that Pakistani injection drug users are twice as likely to donate blood, putting the general population at risk of spreading blood-borne diseases. The researchers advocate for increased screening and interventions to prevent the spread of infections.
Researchers challenge assumption that poverty is a risk factor for non-adherence to HIV medication regimens, citing high treatment adherence rates in South African studies. The editorial argues that delivery systems may compromise confidentiality and risk stigmatization if not based on clear evidence.
Researchers found nearly a third of HIV positive male couples became parents through assisted reproduction, while only one out of ten HIV positive female couples were successful. The study's findings suggest HIV positive men may be more suitable candidates for fertility treatments due to lower infection rates.
A new vaccine has shown promise in inducing an HIV-specific immune response in patients with chronic HIV infection, but further research is needed to evaluate its clinical effect. The vaccine, Remune, was found to increase the production of T helper cells that recognize and attack the virus.
The Vanderbilt Meharry Developmental Center for AIDS Research aims to advance treatment and prevention of HIV/AIDS through collaboration and education. The center will focus on racial disparities and minority populations, building on existing collaborations between the two institutions.